Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $125.67. The company's market cap stands at 155.92B, with a P/E ratio of 19.39 and a dividend yield of 2.5%.
On 2025-12-24, Gilead Sciences(GILD) stock traded between a low of $125.12 and a high of $126.25. Shares are currently priced at $125.67, which is +0.4% above the low and -0.5% below the high.
The Gilead Sciences(GILD)'s current trading volume is 1.5M, compared to an average daily volume of 7.81M.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
GILD News
If you are wondering whether Gilead Sciences is still a smart buy after its big run up, or if the value has already been priced in, you are in the right place t...
Gilead Sciences Inc. (NASDAQ:GILD) on Wednesday agreed to acquire Repare Therapeutics Inc.’s (NASDAQ:RPTX) polymerase theta (Polθ) ATPase inhibitor, RP-3467. R...
Gilead Sciences, Inc. (NASDAQ:GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB) announced on Monday that Gilead has exercised its combined option to exclusivel...
Analyst ratings
72%
of 29 ratingsMore GILD News
H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on Assembly Biosciences (ASMB) with a $50 price target after the company announced that Gilead...
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medica...
Gilead (GILD) Sciences announced an agreement with the U.S. government designed to reduce drug costs for Americans. “This agreement reflects a foundational comm...
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy sales and Descovy for pre-exposure...
Gilead Sciences recently reported that its Phase 3 ARTISTRY-2 trial showed a once-daily bictegravir/lenacapavir pill matched Biktarvy in maintaining HIV viral s...
Gilead (GILD) announced that Keeley Wettan will be appointed executive VP, general counsel, legal and compliance effective immediately. She will join the compan...